Notably, the use of TGF-β blockade antibodies in combination with anti-PD-L1 antibodies reduces TGF-β signaling in stromal cells, thereby enhancing T cell infiltration and triggering potent anti-tumor immune responses [92]. This evidence concerns the gene TGFB1 and neoplasm.